FY2026 EPS Estimate for Palisade Bio Reduced by Analyst

Palisade Bio, Inc. (NASDAQ:PALI – Free Report) – Brookline Capital Markets cut their FY2026 EPS estimates for Palisade Bio in a research report issued on Wednesday, November 11th. Brookline Capital Markets analyst K. Raja now anticipates that the company will post earnings of ($0.24) per share for the year, down from their prior estimate of ($0.21). The consensus estimate for Palisade Bio’s current full-year earnings is ($0.24) per share. Brookline Capital Markets also issued estimates for Palisade Bio’s Q4 2026 earnings at ($0.07) EPS, FY2027 earnings at ($0.29) EPS, FY2028 earnings at ($0.35) EPS, FY2029 earnings at ($0.48) EPS and FY2030 earnings at $0.44 EPS.

Palisade Bio (NASDAQ:PALI – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.01).

A number of other research firms have also recently commented on PALI. Weiss Ratings restated a “sell (e+)” rating on shares of Palisade Bio in a research report on Monday, October 12th. Wall Street Zen lowered Palisade Bio from a “sell” rating to a “strong sell” rating in a report on Saturday. Raymond James Financial started coverage on Palisade Bio in a research note on Thursday, October 8th. They issued an “outperform” rating and a $6.00 target price for the company. Oppenheimer restated an “outperform” rating on shares of Palisade Bio in a report on Wednesday, October 21st. Finally, HC Wainwright dropped their price target on Palisade Bio to $5.00 and set a “buy” rating on the stock in a research report on Wednesday, November 11th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $9.00.

View Our Latest Analysis on PALI

Palisade Bio Price Performance

Shares of NASDAQ PALI opened at $1.12 on Monday. The company’s fifty day moving average is $1.48 and its 200-day moving average is $1.82. The stock has a market cap of $200.79 million, a price-to-earnings ratio of -2.33 and a beta of 1.61. Palisade Bio has a twelve month low of $1.08 and a twelve month high of $2.85.

Institutional Investors Weigh In On Palisade Bio

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Creek Drive Management Group LLC lifted its position in Palisade Bio by 54.5% in the 3rd quarter. Creek Drive Management Group LLC now owns 680,000 shares of the company’s stock valued at $918,000 after acquiring an additional 240,000 shares in the last quarter. ACT Capital Partners L.P. bought a new position in Palisade Bio during the 3rd quarter worth about $415,000. China Universal Asset Management Co. Ltd. increased its holdings in Palisade Bio by 19.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 81,000 shares of the company’s stock worth $117,000 after purchasing an additional 13,110 shares in the last quarter. WINTON GROUP Ltd increased its holdings in Palisade Bio by 180.2% during the 2nd quarter. WINTON GROUP Ltd now owns 32,227 shares of the company’s stock worth $67,000 after purchasing an additional 20,727 shares in the last quarter. Finally, PCG Wealth Advisors LLC acquired a new stake in shares of Palisade Bio in the 2nd quarter valued at about $86,000. 11.79% of the stock is currently owned by institutional investors and hedge funds.

Palisade Bio News Roundup

These are some of the PALI news items that stood out recently:

Palisade Bio Company Profile

(Get Free Report)

Palisade Bio is a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases, with a focus on oral treatments for inflammatory bowel conditions. Its pipeline includes PALI-2108, an investigational, gut-targeted PDE4 inhibitor being developed for ulcerative colitis and fibrostenotic Crohn’s disease. The company has also developed LB1148, an investigational serine protease inhibitor studied for its potential to support bowel function and reduce complications after abdominal surgery.

See Also

Earnings History and Estimates for Palisade Bio (NASDAQ:PALI)

Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.